Edition:
United States

Roche Holding AG (ROG.S)

ROG.S on Virt-X Level 1

276.25CHF
11:31am EDT
Change (% chg)

CHF-0.90 (-0.32%)
Prev Close
CHF277.15
Open
CHF278.65
Day's High
CHF278.80
Day's Low
CHF275.00
Volume
1,130,658
Avg. Vol
1,626,858
52-wk High
CHF283.30
52-wk Low
CHF214.90

Select another date:

Tue, Jun 18 2019

Roche defeats investor lawsuit alleging undisclosed drug researcher conflict

A federal judge has dismissed a lawsuit accusing Roche Holding AG of misleading investors by announcing the results of a study examining how a combination of medications fared in treating breast cancer without disclosing that a key researcher had a conflict of interest.

Roche's combo lymphoma treatment wins U.S. FDA approval

(This June 10 story deletes paragraph 9 to clarify that retreatment with Polivy has not been studied.)

CORRECTED-UPDATE 3-Roche's combo lymphoma treatment wins U.S. FDA approval

June 10 The U.S. Food and Drug Administration on Monday granted earlier-than-expected approval to Roche Holding AG's antibody- Polivy for treatment of patients with advanced lymphoma.

BRIEF-Roche: Rituximab Phase III Study Met Primary Endpoint

* PHASE III PEMPHIX STUDY SHOWED THAT MABTHERA/RITUXAN (RITUXIMAB) IS SUPERIOR TO STANDARD OF CARE IN ACHIEVING SUSTAINED REMISSION IN PATIENTS WITH PEMPHIGUS VULGARIS

BRIEF-FDA Grants Priority Review To Roche’S Rituximab In Children With Blood Vessel Disorders

* FDA GRANTS PRIORITY REVIEW TO GENENTECH’S RITUXAN (RITUXIMAB) IN CHILDREN WITH TWO RARE BLOOD VESSEL DISORDERS

BRIEF-Roche Holding Announces Positive Phase II Lupus Nephritis Study Results For Genentech's Gazyva (Obinutuzumab)

* GENENTECH’S GAZYVA (OBINUTUZUMAB) DELIVERS POSITIVE TOPLINE RESULTS FOR PHASE II LUPUS NEPHRITIS STUDY

BRIEF-Roche Says U.S. List Price For 4-Month Course Of Polivy Is $90,000 On Average

* SAYS U.S. LIST PRICE FOR 4-MONTH COURSE OF POLIVY IS $90,000 ON AVERAGE; POLIVY DOSAGE BASED ON PATIENT WEIGHT Further company coverage:

Roche's combo lymphoma treatment wins FDA's accelerated approval

June 10 The U.S. Food and Drug Administration granted accelerated approval to Roche Holding AG's combo lymphoma treatment for previously treated patients, the company said on Monday

BRIEF-Roche And Spark Therapeutics Receive Information Request From Federal Trade Commission

* ROCHE AND SPARK THERAPEUTICS, INC. RECEIVE REQUEST FOR ADDITIONAL INFORMATION FROM FTC UNDER HART-SCOTT-RODINO ACT AND ANNOUNCE EXTENSION OF TENDER OFFER FOR SHARES OF SPARK THERAPEUTICS, INC.

BRIEF-Roche Holding Announces Phase III CLL14 Results For Venclexta/Venclyxto With Gazyva/Gazyvaro

* PIVOTAL PHASE III CLL14 RESULTS FOR VENCLEXTA/VENCLYXTO IN COMBINATION WITH GAZYVA/GAZYVARO FOR CHRONIC LYMPHOCYTIC LEUKAEMIA PRESENTED AT ASCO 2019 AND PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE

Select another date: